Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00035024.xml
Thromb Haemost 2012; 108(03): 583-585
DOI: 10.1160/TH12-03-0149
DOI: 10.1160/TH12-03-0149
Letters to the Editor
Life-threatening bleeding in four patients with an unusual excessive response to dabigatran: Implications for emergency surgery and resuscitation
Further Information
Publication History
Received:
09 March 2012
Accepted after minor revision:
06 June 2012
Publication Date:
25 November 2017 (online)
-
References
- 1 Freyburger G, Macouillard G, Labrouche S. et al. Coagulation parameters in patients receiving dabigatran etexilate or rivaroxaban: two observational studies in patients undergoing total hip or total knee replacement. Thromb Res 2011; 127: 457-465.
- 2 Stangier J, Feuring M. Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran. Blood Coagul Fibrinolysis 2012; 23: 138-143.
- 3 van Ryn J, Stangier J, Haertter S. et al. Dabigatran etexilate - a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010; 29: 103.
- 4 Eriksson BI, Dahl OE, Rosencher N. et al. and REMODEL Study Group. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 2007; 370: 949-956. Erratum in: Lancet 2007; 370: 2004.
- 5 Eriksson BI, Dahl OE, Rosencher N. et al. REMODEL Study Group>. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 2007; 05: 2178-2185.
- 6 CHMP Assessment report for Pradaxa. Procedure No. EMEA/H/C/829. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000829/WC500041062.pdf Accessed November 15, 2011.
- 7 US FDA Advisory Committee Briefing Document. August 27, 2010 Available at: http://www.fda.gov/downloads/AdvisoryCommittees/Committees-MeetingMaterials/Drugs/CardiovascularandRenalDrugs%20AdvisoryCommittee/UCM226009.pdf?bcsi%20scan%2033FB12C90BF1B18A_1 Accessed November 15, 2011.
- 8 CHMP Assessment report for Pradaxa. Procedure No. EMEA/H/C/000829/X/13/G. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000829/WC500110875.pdf Acessed November 15, 2011.
- 9 Connolly SJ, Ezekowitz MD, Yusuf S. et al. RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151.
- 10 Hankey GJ, Eikelboom Jw. Dabigatran etexilate: a new oral thrombin inhibitor Circulation. 2011; 123: 1436-1450.
- 11 Safety advisory issued by the Japanese Ministry of Health, Labour and Welfare regarding Pradaxa (dabigatran etexilate). Available at: http://www.psdh.gov.hk/eps/ControlServlet?Function-Name=EPS&FunctionID=NEWS&action_type=SHOW_NEWS&seq=562550&news_id=14642 Accessed November 15, 2011.
- 12 Guidelines for management of bleeding with dabigatran - for possible inclusion into local management protocols. Available at: http://www.pharmac.govt.nz/2011/06/13/Dabigatran%20bleeding%20management.pdf Accessed January 24, 2012.
- 13 Food and Drug Administration. Pradaxa (dabigatran etexilate mesylate): Drug safety communication--Safety review of post-market reports of serious bleeding events. December 7, 2011 Available at: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm282820.htm Accessed January 24, 2012.
- 14 Bell S, Nand J, Spriggs D. New antithrombotic drugs for atrial fibrillation : caution is needed. Lancet 2012; 379: e24 author reply e24-25.
- 15 Legrand M, Mateo J, Aribaud A. et al. The Use of Dabigatran in Elderly patients. Arch Intern Med 2011; 171: 1285-1286.
- 16 Therapeutic Goods Administration. Safety Advisory. Available at: http://www.tga.gov.au/safety/alerts-medicine-dabigatran-111005.htm Accessed November 15, 2011.
- 17 Wann LS, Curtis AB, Ellenbogen KA. et al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol 2011; 57: 1330-1337.
- 18 Eerenberg ES, Kamphuisen PW, Sijpkens MK. et al. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011; 124: 1573-1579.